LENZ Therapeutics Reports Preliminary Q4 2025 Results, Highlights VIZZ Launch

Published on January 9, 2026
SAN DIEGO, Calif.—LENZ Therapeutics, Inc. (Nasdaq: LENZ), a pharmaceutical company focused on the commercialization of VIZZ (aceclidine ophthalmic solution) 1.44%, has announced certain preliminary unaudited financial results for the fourth quarter ended December 31, 2025 and recent corporate updates. Approved by the FDA in August 2025, VIZZ is a once-daily aceclidine-based eye drop for the treatment of age-related presbyopia. The company reported the first commercial product sale of VIZZ in October 2025, with VIZZ net product revenue of approximately $1.6 million in the fourth quarter of 2025.
Continue reading on website
Other news

LensCrafters Continues ‘Dedicated to Everyday Excellence’ Campaign in 2026 With Award Winning Anisha Haji, OD

January 9, 2026
NEW YORK—LensCrafters, part of EssilorLuxottica and one of the largest optical retailers in North America, has announced the continuation of its “Dedicated to Everyday Excellence” campaign in collaboration with Anisha Haji, OD, a LensCrafters independent optometrist. Launched in 2025, this 360-degree omnichannel initiative celebrates professionals whose expertise, trust and commitment define their

The Vision Council Unveils Panel Topics for Its 2026 Executive Summit

January 9, 2026
ALEXANDRIA, Va.—The Vision Council has announced the topics for each of the three panel discussions at its upcoming 2026 Executive Summit set to take place on January 26 to 28 at the Ritz-Carlton, in Amelia Island, Fla. The panels will focus on the intersection of hearing and eyecare, artificial intelligence in optical, and government relations. Attendees were invited to submit their own questions